Induction Therapy and Therapeutic Antibodies

Area of Science:

• Immunology
• Transplantation Medicine
• Pharmacology

Background:

• Allograft rejection, mediated by cellular and humoral pathways targeting alloantigens, is a primary challenge in solid organ transplantation.
• The highest risk of rejection occurs within the first post-transplant year, necessitating intensive immunosuppression.
• Induction therapy aims to mitigate this early rejection risk using potent immunosuppressive agents.

Purpose of the Study:

• To review the role and mechanisms of antibody therapies in solid organ transplantation.
• To highlight the application of antibody therapies in induction, treatment, and desensitization protocols.
• To discuss the immunomodulatory effects and cell depletion capabilities of antibody therapies.

Main Methods:

• Review of existing literature on antibody therapies in solid organ transplantation.
• Analysis of antibody mechanisms targeting T-cell activation and alloantibodies.
• Examination of antibody use in induction, rejection treatment, and desensitization.

Main Results:

• Antibody therapies, including monoclonal and polyclonal antibodies, are effective in induction therapy.
• These therapies demonstrate potent immunomodulatory effects and can lead to durable immune cell depletion.
• Antibodies are utilized for treating active allograft rejection and modulating alloantibodies in desensitization.

Conclusions:

• Antibody therapies are essential components of modern solid organ transplantation protocols.
• Their use extends beyond induction to include rejection treatment and desensitization, improving graft durability.
• Effective management of allograft rejection relies on strategic application of potent antibody-based immunosuppression.